Company intelligence / Profile preview
CIS BIOPHARMA
Bubendorf, Basel-Landschaft, Switzerlandcisbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CIS BIOPHARMA has demonstrated preclinical efficacy of its lead ADC program CBO‑001 against SCLC. Their radioligand targeting L1CAM has shown strong activity in ovarian cancer xenograft models. Comparative preclinical data suggest best-in-class potential for their programs. Clinical trials are expected to begin in 2025
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateRadiopharmaceuticalMonoclonal antibodyNanobody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaborations with patient organizations, clinics, physicians, scientists and financial partners are mentioned but no specific major pharma partnerships disclosed yet
Beyond the preview
Go deeper on CIS BIOPHARMA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIS BIOPHARMA.